Table 2.
Estimated impact of gonorrhoea vaccination strategies among men who have sex with men when using a vaccine providing 40% protection for 4 years
|
Number of vaccine doses administered, thousands |
Number of gonorrhoea cases averted over 10 years, thousands | Value*per dose, £ | |||
|---|---|---|---|---|---|
| Year 1 | Year 10 | Years 1–10 total | |||
| Vaccination on diagnosis | 24·6 (20·3–28·8) | 11·7 (8·8–14·8) | 172·9 (136·4–208·6) | 85·8 (49·3–131·0) | 80 (41–138) |
| Vaccination according to risk | 54·4 (38·3–78·0) | 16·4 (15·2–18·0) | 291·4 (249·6–333·7) | 181·0 (75·6–295·7) | 99 (48–147) |
| Vaccination on attendance | 180·2 (160·6–200·3) | 83·6 (75·6–88·3) | 1264·4 (1119·7–1370·2) | 182·2 (77·3–296·5) | 23 (9–42) |
Results are median (95% credible interval). Estimates presented are relative to the lower-bound baseline (in which there is no vaccination and trends in time-varying behavioural parameters stabilise). QALY=quality-adjusted life-year.
*
The value of vaccination per dose was calculated by summing the averted costs of testing and treatment, and the monetary value of averted QALY losses with a QALY valued at £20 000, then dividing this monetary benefit of vaccination by the number of vaccine doses administered in sexual health clinics, considering a 10-year period with discounting at 3·5% per year.